Mechanisms of osteolytic and osteoblastic skeletal lesions

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Lytic and blastic bone metastases represent extremes of a continuum, with most patients having a mixture of osteolytic and osteoblastic components in their lesions. This chapter provides the mechanisms responsible for osteolytic and osteoblastic metastasis, and also provides examples of how their identification has resulted in the development of new treatments for cancer in bone (CIB) patients. Multiple mechanisms contribute to tumor cells homing to bone and the subsequent development of bone lesions. Adhesion molecules expressed on tumor cells and cellular products from tumor cells also increase bone metastasis. In osteolytic metastasis and multiple myeloma (MM), the bone remodeling process is imbalanced, or uncoupled, with increased osteoclastic bone resorption driven by osteoclast-activating factors produced by the tumor cells, or by cells in the bone microenvironment in response to the tumor cells. Immune cell tumor cell interactions can suppress antitumor immune responses, and are an emerging therapeutic target for modulating the growth of tumors.

Original languageEnglish (US)
Title of host publicationPrimer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
Publisherwiley
Pages739-742
Number of pages4
ISBN (Electronic)9781119266594
ISBN (Print)9781119266563
DOIs
StatePublished - Jan 1 2018

Fingerprint

Bone
Tumors
Cells
Neoplasms
Neoplasm Metastasis
Bone and Bones
Bone Neoplasms
Bone Remodeling
Bone Development
Bone Resorption
Multiple Myeloma
Cell Communication
Adhesion
Molecules
Therapeutics
Growth

Keywords

  • Antitumor immune responses
  • Multiple myeloma
  • Osteoblastic metastasis
  • Osteolytic metastasis
  • Skeletal lesions

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Roodman, G. D., & Guise, T. (2018). Mechanisms of osteolytic and osteoblastic skeletal lesions. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (pp. 739-742). wiley. https://doi.org/10.1002/9781119266594.ch95

Mechanisms of osteolytic and osteoblastic skeletal lesions. / Roodman, G. David; Guise, Theresa.

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. wiley, 2018. p. 739-742.

Research output: Chapter in Book/Report/Conference proceedingChapter

Roodman, GD & Guise, T 2018, Mechanisms of osteolytic and osteoblastic skeletal lesions. in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. wiley, pp. 739-742. https://doi.org/10.1002/9781119266594.ch95
Roodman GD, Guise T. Mechanisms of osteolytic and osteoblastic skeletal lesions. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. wiley. 2018. p. 739-742 https://doi.org/10.1002/9781119266594.ch95
Roodman, G. David ; Guise, Theresa. / Mechanisms of osteolytic and osteoblastic skeletal lesions. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. wiley, 2018. pp. 739-742
@inbook{77b5a2cc6d95401cb9e86799260e4359,
title = "Mechanisms of osteolytic and osteoblastic skeletal lesions",
abstract = "Lytic and blastic bone metastases represent extremes of a continuum, with most patients having a mixture of osteolytic and osteoblastic components in their lesions. This chapter provides the mechanisms responsible for osteolytic and osteoblastic metastasis, and also provides examples of how their identification has resulted in the development of new treatments for cancer in bone (CIB) patients. Multiple mechanisms contribute to tumor cells homing to bone and the subsequent development of bone lesions. Adhesion molecules expressed on tumor cells and cellular products from tumor cells also increase bone metastasis. In osteolytic metastasis and multiple myeloma (MM), the bone remodeling process is imbalanced, or uncoupled, with increased osteoclastic bone resorption driven by osteoclast-activating factors produced by the tumor cells, or by cells in the bone microenvironment in response to the tumor cells. Immune cell tumor cell interactions can suppress antitumor immune responses, and are an emerging therapeutic target for modulating the growth of tumors.",
keywords = "Antitumor immune responses, Multiple myeloma, Osteoblastic metastasis, Osteolytic metastasis, Skeletal lesions",
author = "Roodman, {G. David} and Theresa Guise",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/9781119266594.ch95",
language = "English (US)",
isbn = "9781119266563",
pages = "739--742",
booktitle = "Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism",
publisher = "wiley",

}

TY - CHAP

T1 - Mechanisms of osteolytic and osteoblastic skeletal lesions

AU - Roodman, G. David

AU - Guise, Theresa

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Lytic and blastic bone metastases represent extremes of a continuum, with most patients having a mixture of osteolytic and osteoblastic components in their lesions. This chapter provides the mechanisms responsible for osteolytic and osteoblastic metastasis, and also provides examples of how their identification has resulted in the development of new treatments for cancer in bone (CIB) patients. Multiple mechanisms contribute to tumor cells homing to bone and the subsequent development of bone lesions. Adhesion molecules expressed on tumor cells and cellular products from tumor cells also increase bone metastasis. In osteolytic metastasis and multiple myeloma (MM), the bone remodeling process is imbalanced, or uncoupled, with increased osteoclastic bone resorption driven by osteoclast-activating factors produced by the tumor cells, or by cells in the bone microenvironment in response to the tumor cells. Immune cell tumor cell interactions can suppress antitumor immune responses, and are an emerging therapeutic target for modulating the growth of tumors.

AB - Lytic and blastic bone metastases represent extremes of a continuum, with most patients having a mixture of osteolytic and osteoblastic components in their lesions. This chapter provides the mechanisms responsible for osteolytic and osteoblastic metastasis, and also provides examples of how their identification has resulted in the development of new treatments for cancer in bone (CIB) patients. Multiple mechanisms contribute to tumor cells homing to bone and the subsequent development of bone lesions. Adhesion molecules expressed on tumor cells and cellular products from tumor cells also increase bone metastasis. In osteolytic metastasis and multiple myeloma (MM), the bone remodeling process is imbalanced, or uncoupled, with increased osteoclastic bone resorption driven by osteoclast-activating factors produced by the tumor cells, or by cells in the bone microenvironment in response to the tumor cells. Immune cell tumor cell interactions can suppress antitumor immune responses, and are an emerging therapeutic target for modulating the growth of tumors.

KW - Antitumor immune responses

KW - Multiple myeloma

KW - Osteoblastic metastasis

KW - Osteolytic metastasis

KW - Skeletal lesions

UR - http://www.scopus.com/inward/record.url?scp=85060593622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060593622&partnerID=8YFLogxK

U2 - 10.1002/9781119266594.ch95

DO - 10.1002/9781119266594.ch95

M3 - Chapter

AN - SCOPUS:85060593622

SN - 9781119266563

SP - 739

EP - 742

BT - Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism

PB - wiley

ER -